Table 3.
Sensitivity analysis for prevalence of gastrointestinal bleeding risk factors in overall population (%)
| 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | ≥ 85 yr | |
| Comorbid conditions | ||||||||||||||
| Peptic ulcer | 3.84% | 4.80% | 4.92% | 5.49% | 7.61% | 8.47% | 10.87% | 12.45% | 14.20% | 15.49% | 17.50% | 16.08% | 13.72% | 9.95% |
| Diabetes | 0.31% | 0.49% | 0.96% | 1.76% | 3.27% | 5.68% | 8.78% | 13.17% | 18.18% | 22.04% | 25.48% | 25.96% | 23.55% | 16.13% |
| Chronic liver disease | 2.17% | 2.99% | 3.74% | 4.40% | 4.76% | 5.99% | 7.55% | 8.68% | 9.09% | 9.03% | 8.01% | 6.91% | 5.65% | 3.96% |
| Chronic renal failure | 0.03% | 0.06% | 0.09% | 0.14% | 0.23% | 0.28% | 0.39% | 0.59% | 0.88% | 1.13% | 1.66% | 1.84% | 1.96% | 1.66% |
| Gastroesophageal reflux disease | 6.02% | 8.34% | 8.88% | 9.92% | 13.22% | 13.63% | 17.18% | 19.11% | 22.11% | 22.85% | 23.93% | 20.94% | 17.29% | 11.43% |
| Concomitant drugs1 | ||||||||||||||
| Aspirin | 0.04% | 0.09% | 0.18% | 0.50% | 1.26% | 2.84% | 5.97% | 10.67% | 16.17% | 20.60% | 25.24% | 26.59% | 26.35% | 20.75% |
| Clopidogrel | 0.01% | 0.01% | 0.04% | 0.10% | 0.28% | 0.59% | 1.17% | 2.25% | 3.83% | 5.47% | 7.58% | 9.03% | 10.00% | 7.75% |
| Cilostazol | 0.00% | 0.00% | 0.02% | 0.04% | 0.13% | 0.25% | 0.54% | 0.96% | 1.48% | 2.15% | 2.83% | 3.39% | 3.21% | 2.45% |
| NSAIDs | 2.34% | 3.31% | 4.56% | 6.29% | 7.35% | 9.96% | 14.69% | 18.52% | 23.02% | 27.50% | 31.07% | 31.68% | 30.34% | 22.76% |
| Steroid | 0.88% | 1.07% | 1.28% | 1.62% | 1.88% | 2.21% | 2.91% | 3.50% | 4.43% | 5.54% | 6.59% | 6.72% | 6.07% | 4.58% |
| Anticoagulants2 | 0.01% | 0.01% | 0.03% | 0.04% | 0.07% | 0.10% | 0.16% | 0.25% | 0.34% | 0.53% | 0.73% | 0.96% | 0.73% | 0.50% |
| SSRI | 0.21% | 0.22% | 0.21% | 0.27% | 0.32% | 0.38% | 0.50% | 0.55% | 0.74% | 1.13% | 1.53% | 1.89% | 2.13% | 1.70% |
| No. of risk factors | ||||||||||||||
| (without H. pylori prevalence imputation) | ||||||||||||||
| ≥ 1 | 13.32% | 17.55% | 19.61% | 23.22% | 29.38% | 34.49% | 44.88% | 53.68% | 62.87% | 68.98% | 74.57% | 74.65% | 71.74% | 58.61% |
| ≥ 2 | 2.25% | 3.29% | 4.42% | 5.97% | 8.57% | 11.89% | 18.42% | 24.98% | 33.02% | 39.09% | 45.26% | 45.36% | 41.69% | 29.63% |
| ≥ 3 | 0.29% | 0.48% | 0.74% | 1.18% | 1.99% | 3.20% | 5.72% | 8.93% | 13.23% | 17.29% | 21.32% | 21.25% | 18.75% | 11.07% |
| No. of risk factors | ||||||||||||||
| (after H. pylori prevalence imputation) | ||||||||||||||
| ≥ 1 | 36.21% | 39.37% | 53.24% | 55.64% | 66.45% | 68.97% | 78.69% | 82.11% | 85.68% | 88.13% | 89.66% | 89.52% | 88.55% | 83.72% |
| ≥ 2 | 5.12% | 7.08% | 10.87% | 13.30% | 19.66% | 23.81% | 34.58% | 42.48% | 51.41% | 57.73% | 62.40% | 62.59% | 59.14% | 46.84% |
| ≥ 3 | 0.78% | 1.21% | 2.32% | 3.24% | 5.45% | 7.75% | 13.52% | 18.90% | 25.56% | 30.79% | 35.35% | 35.09% | 32.49% | 21.95% |
1
Subjects who were prescribed 60 d or more in 2013;
2
Warfarin, rivaroxaban, dabigatran, and apixaban were included. NSAIDs: Non-steroidal anti-inflammatory drugs; SSRI: Selective serotonin reuptake inhibitor.